,0
0,Bristol Myers' (BMY) Opdivo SC Meets Kidney Cancer Study Goals
1,Earnings Preview: Bristol Myers Squibb (BMY) Q3 Earnings Expected to Decline
2,Earnings Preview: United States Steel (X) Q3 Earnings Expected to DeclineZacks
3,Earnings Preview: South State (SSB) Q3 Earnings Expected to DeclineZacks
4,3 Things About Bristol Myers Squibb That Smart Investors Know
5,Could Bristol Myers Squibb Stock Help You Become a Millionaire?
6,UPDATE 2-Bristol Myers' injectable form of Opdivo meets main goal in kidney cancer trial
7,Phase 3 CheckMate -67T Trial of Subcutaneous Nivolumab (nivolumab and hyaluronidase) Meets Co-Primary Endpoints in Advanced or Metastatic Clear Cell Renal Cell Carcinoma
8,The Robert A. Winn Diversity in Clinical Trials Award Announces Third Group of Physicians in Program to Increase Diversity in Clinical Trials
9,2 High-Yield Dividend Stocks to Buy Now
10,Neoadjuvant Opdivo (nivolumab) with Chemotherapy Provides Benefits for Patients with Resectable Non-Small Cell Lung Cancer Across PD-L1 Expression Levels with Three-Year Follow Up in CheckMate -816 Trial
11,Opdivo (nivolumab) in Combination with Cisplatin-Based Chemotherapy Followed by Opdivo Demonstrates Significant Survival Benefits for Cisplatin-Eligible Patients with Unresectable or Metastatic Urothelial Carcinoma in Phase 3 CheckMate -901 Trial
